Advances and challenges in the management of essential thrombocythemia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Therapeutic Advances in Hematology

• Publication date

  2015-04-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2040620715580068PMID 26137205PMCID PMC4480522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

  2017cited by this paper
• Essential thrombocythemia: Baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients☆

  2015cited by this paper
• Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history

  2015cited by this paper
• [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].

  2015cited by this paper
• An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

  2014cited by this paper
• Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

  2014cited by this paper
• Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients

  2014cited by this paper
• WHO‐histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes

  2014cited by this paper
• JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms

  2014cited by this paper
• [Clinical characteristics and risk factors for major thrombosis in 604 Chinese patients with low-risk essential thrombocythemia].

  2014cited by this paper
• Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

  2014cited by this paper
• Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

  2014cited by this paper
• Calreticulin mutations and long-term survival in essential thrombocythemia

  2014cited by this paper
• CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

  2014cited by this paper
• Treatment of Essential Thrombocythemia in Europe: An Observational Study of 3649 High-Risk Patients in Exels

  2014cited by this paper
• Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients

  2014cited by this paper
• Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN)

  2014cited by this paper
• Interferon alfa therapy in CALR-mutated essential thrombocythemia.

  2014influential reference
• Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia

  2014cited by this paper
• JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events

  2014cited by this paper
• CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

  2014cited by this paper
• Masked polycythemia Vera (mPV): Results of an international study

  2014cited by this paper
• High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms

  2014cited by this paper
• Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

  2013cited by this paper
• ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.

  2013cited by this paper
• Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

  2013cited by this paper
• Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

  2013cited by this paper
• Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

  2013cited by this paper
• Personalized management of essential thrombocythemia—application of recent evidence to clinical practice

  2013cited by this paper
• Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

  2013cited by this paper
• Somatic mutations of calreticulin in myeloproliferative neoplasms.

  2013cited by this paper
• thrombocythemia and polycythemia vera transformation and new nonmyeloid malignancies in essential gene predisposes to leukemic XPD A polymorphism in the

  2013cited by this paper
• Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

  2013cited by this paper
• Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

  2013cited by this paper
• Cytoreduction plus low‐dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high‐risk essential thrombocythaemia: an observational study

  2013cited by this paper
• Intracellular deoxyribonucleotide pool imbalance and DNA damage in cells treated with hydroxyurea, an inhibitor of ribonucleotide reductase.

  2013cited by this paper
• Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.

  2012cited by this paper
• Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

  2012cited by this paper
• Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

  2012cited by this paper
• A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

  2012cited by this paper
• Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

  2012cited by this paper
• Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

  2012cited by this paper
• Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.

  2011cited by this paper
• Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

  2011cited by this paper
• Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.

  2011cited by this paper
• Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

  2011cited by this paper
• Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

  2011cited by this paper
• A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

  2011cited by this paper
• Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

  2011cited by this paper
• The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

  2011cited by this paper
• Anagrelide represses GATA‐1 and FOG‐1 expression without interfering with thrombopoietin receptor signal transduction

  2010cited by this paper
• Guideline for investigation and management of adults and children presenting with a thrombocytosis

  2010cited by this paper
• The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.

  2010cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2010cited by this paper
• Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis

  2010cited by this paper
• A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

  2010cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2009cited by this paper
• Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.

  2009cited by this paper
• Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

  2009cited by this paper
• Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low‐risk essential thrombocythemia and polycythemia vera

  2009cited by this paper
• Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

  2009cited by this paper
• JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

  2009cited by this paper
• Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.

  2009cited by this paper
• The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.

  2008cited by this paper
• Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

  2008cited by this paper
• Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.

  2008cited by this paper
• Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

  2008influential reference
• Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia

  2008cited by this paper
• Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

  2007cited by this paper
• Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

  2007cited by this paper
• Leukocytosis and risk stratification assessment in essential thrombocythemia.

  2007cited by this paper
• Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage

  2006cited by this paper
• Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology

  2006cited by this paper
• A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

  2006cited by this paper
• Leg ulcers in elderly on hydroxyurea: a single center experience in Ph− myeloproliferative disorders and review of literature

  2006cited by this paper
• A Phase II Trial of Pegylated Interferon -2b Therapy for Polycythemia Vera and Essential Thrombocythemia Feasibility, Clinical and Biologic Effects, and Impact on Quality of Life

  2006cited by this paper
• A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders

  2006cited by this paper
• Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study.

  2005cited by this paper
• Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

  2005cited by this paper
• Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.

  2005cited by this paper
• Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.

  2005cited by this paper
• Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

  2005cited by this paper
• Proteolytic cleavage of protein S during the hemostatic response

  2005cited by this paper
• Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

  2005cited by this paper
• Anagrelide for thrombocytosis in myeloproliferative disorders

  2004cited by this paper
• Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

  2004cited by this paper
• Efficacy and safety of low-dose aspirin in polycythemia vera.

  2004cited by this paper
• Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera

  2004cited by this paper
• Low-Dose Aspirin in Polycythemia Vera

  2004cited by this paper
• Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.

  2004cited by this paper
• Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients.

  2003cited by this paper
• Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

  2003cited by this paper
• Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review

  2002cited by this paper

• CALR-mutated myeloproliferative neoplasms

  2025cites this paper
• Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

  2022cites this paper
• SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.

  2022cites this paper
• Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension

  2021cites this paper
• Bioinspired Extracellular Vesicles: Lessons Learned From Nature for Biomedicine and Bioengineering

  2020cites this paper
• Austrian recommendations for the management of essential thrombocythemia

  2020cites this paper
• Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl

  2019cites this paper
• EVALUATION OF ASPIRIN RESPONSIVENESS IN ESSENTIAL THROMBOCYTHEMIA PATIENTS

  2018cites this paper
• Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

  2017cites this paper
• Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

  2017cites this paper
• Investigation of T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) polymorphisms in essential thrombocythaemia (ET)

  2017cites this paper
• Unmet Clinical Needs of Antithrombotic Treatment in BCR/ABL-Negative Myeloproliferative Neoplasms

  2016cites this paper
• Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.

  2015cites this paper
• Clinico-Hematological Profile and Risk Stratification in Patients with Essential Thrombocythemia: Experience from Pakistan.

  2015influential citation